OR WAIT null SECS
November 21, 2024
Video
Ahmad Masri, MD, MS, discusses data from the FOREST-HCM trial examining effects of aficamten in patients with oHCM eligible for septal reduction therapy at baseline.
Ahmad Masri, MD, MS, discusses a study from AHA 2024 detailing changing risk profiles and outcomes in trials among patients with ATTR-CM.
November 20, 2024
Marianna Fontana, MD, PhD discusses Phase 1 interim results on the CRISPR-based gene-editing therapy, nex-z, for ATTR-CM.
November 19, 2024
Marianna Fontana, MD, PhD describes the prognostic importance of a decline in eGFR in a retrospective cohort of patients with ATTR-CM.
November 18, 2024
Article
Sacubitril/valsartan reduced the risk of heart damage among high-risk cancer patients treated with anthracycline chemotherapy agents.
November 16, 2024
A single dose of nex-z achieved consistent and rapid reductions in serum TTR levels over 12 months of follow-up in patients with ATTR-CM.
November 13, 2024
Masri discussed the new phase 3 trial of Intellia’s NTLA-2001 or nex-z.
October 23, 2024
Masri previewed data to be presented at the AHA 2024 Scientific Sessions and shared his excitement for the ongoing phase 3 trial of NTLA-2001.
October 11, 2024
The sNDA submission to the FDA included a Priority Review Voucher, which commits the regulatory agency to an accelerated review timeline.
October 04, 2024
A review of 5 highly anticipated FDA decisions expected by year-end, including acoramidis for ATTR-CM, olezarsen for FCS, sotagliflozin for T1D and CKD, and more.
